- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01075438
Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients
Descriptive Immunogenicity of 2 Doses of Pneumococcal 7-valent Conjugate Vaccine (Prevenar®, Wyeth Lederle) Followed by Pneumococcal Polysaccharide Vaccine (Pneumovax® Aventis Pasteur MSD) in Ataxia-telangiectasia Patients
Ataxia-telangiectasia (AT) is a rare genetic disorder characterized by gait disorders, neuromotor dysfunction, eye abnormalities and immune deficiency. AT patients are vulnerable to cancer and infection and usually die during their 2nd or 3rd decade due to these complications. The main cause of death is respiratory infections because these patients are known to have severe type of immunodeficiency. Consequently, pneumonia is the most common infection seen in AT patients, and is usually caused by S. pneumoniae. Therefore, a routine schedule of pneumococcal vaccine is highly recommended in AT cases where immunoglobulin replacement therapy was not already initiated.
Until recently, AT patients were immunized with the pneumococcal polysaccharide vaccine (PPV23, Pneumovax® Aventis Pasteur MSD). However, data have shown that they do not respond well to these vaccines. Recently, the Israeli Ministry of Health has approved the pneumococcal 7-valent conjugate vaccine (PCV7, Prevenar®, Wyeth Lederle) for AT patients of all ages. This conjugate vaccine is known to stimulate the immune system through a different mechanism and the response is expected to be higher. The approved Israeli schedule for immunization of AT patients includes children older than 2 years that are entitled to receive 2 doses of PCV7 (8 weeks apart) boosted by PPV23, eight weeks after the second dose of PCV7. Assessment of the antibody response of such pneumococcal vaccination protocol in AT patients has never been performed.
The "Safra" Children's Hospital is the national multi-disciplinary center caring for AT patients. Approximately 50 patients from all over the country (including Jewish, Druze, Bedouin and other Muslim patients - 3 of whom are Palestinians) are followed in the clinic on a monthly basis.
Approximately 20 AT patients are not receiving IVIG replacement therapy, therefore are entitled to receive pneumococcal vaccination as stated above (mean age 10.6, 3 -23 years, 3 less than 5 years)
The aim of this study is to evaluate the responsiveness, determined by specific antibody production, of AT patients receiving this new vaccine protocol.
Study Overview
Status
Conditions
Detailed Description
Ataxia-telangiectasia (AT) is a rare progressive neurodegenerative autosomal recessive disorder characterized by cerebellar ataxia, neuromotor dysfunction, oculocutaneous telangiectasia and immunodeficiency. AT patients are vulnerable to cancer and infection and usually die during their 2nd or 3rd decade due to these complications. Life expectancy does not correlate well with severity of neurological impairment. The main cause of death is respiratory infections because these patients are known to have severe type of immunodeficiency. The immunodeficiency of AT patient consists of both humoral defect (immunoglobulin deficiency and reduced response to polysaccharide antigens) and cell-mediated defect (reduced lymphocytes number and function). Consequently, pneumonia is the most common infection seen in AT patients, and is usually caused by S. pneumoniae. Therefore, a routine schedule of pneumococcal vaccine is highly recommended in AT cases where immunoglobulin replacement therapy was not already initiated.
Until recently, AT patients were immunized with the pneumococcal polysaccharide vaccine (PPV23, Pneumovax® Aventis Pasteur MSD). However, data have shown that they do not respond well to these vaccine mainly because of their reduced response to polysaccharide stimulation. Recently, the Israeli Ministry of Health has approved the pneumococcal 7-valent conjugate vaccine (PCV7, Prevenar®, Wyeth Lederle) for AT patients of all ages. In contrast to polysaccharide vaccines, this conjugate vaccine is known to stimulate the immune system through T-cell dependent mechanism, and therefore the response is expected to be higher. The approved Israeli schedule for immunization of AT patients includes children older than 2 years that are entitled to receive 2 doses of PCV7 (8 weeks apart) boosted by PPV23, eight weeks after the second dose of PCV7. Assessment of the immunogenicity of such pneumococcal vaccination protocol in AT patients has never been performed.
The "Safra" Children's Hospital is the national multi-disciplinary center caring for AT patients. Approximately 50 patients from all over the country (including Jewish, Druze, Bedouin and other Muslim patients - 3 of whom are Palestinians) are followed in the clinic on a monthly basis.
Approximately 20 AT patients are not receiving IVIG replacement therapy, therefore are entitled to receive pneumococcal vaccination as stated above (mean age 10.6, 3 -23 years, 3 less than 5 years.
The aim of this study is to evaluate the responsiveness, determined by specific antibody production, of AT patients receiving the new vaccine protocol that was recently approved to use by the Israeli Ministry of Health.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Galia Barkai, MD
- Phone Number: 972-3-530-5978
- Email: Galia.Barkai@sheba.health.gov.il
Study Locations
-
-
-
Tel Hashomer, Israel, 52621
- Chaim Sheba Medical Center
-
Contact:
- Galia Barkai, MD
- Phone Number: 972-3-5305978
- Email: Galia.Barkai@sheba.health.gov.il
-
Principal Investigator:
- Galia Barkai, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- AT patients attending the national AT clinic
- 2+ years of age
- Agree to join this study
Exclusion Criteria:
- Patients on regular immunoglobulin replacement therapy (other patients who are not on replacement therapy but have received IVIG 3 months or less before the beginning of the study)
- Current infection
- Previous serious adverse reactions to vaccination
- Administration of other vaccines within 4 weeks before administration of study vaccine or plan for vaccination 26 weeks following the first vaccine (PCV7)
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary end point will be levels of antibodies against 13 serotypes of streptococcus pneumoniae following vaccination with 2 doses of PCV7 and 1 dose of PPV23. All endpoints will include both ELISA and OPA antibodies.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Immunologic Deficiency Syndromes
- Immune System Diseases
- Neurologic Manifestations
- Genetic Diseases, Inborn
- Dyskinesias
- DNA Repair-Deficiency Disorders
- Neurocutaneous Syndromes
- Cerebellar Diseases
- Primary Immunodeficiency Diseases
- Spinocerebellar Ataxias
- Ataxia
- Telangiectasis
- Cerebellar Ataxia
- Ataxia Telangiectasia
- Physiological Effects of Drugs
- Immunologic Factors
- Vaccines
- Heptavalent Pneumococcal Conjugate Vaccine
Other Study ID Numbers
- SHEBA-09-7444-GB-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ataxia Telangiectasia
-
Matrix Biomed, Inc.The University of Texas Health Science Center, HoustonNot yet recruitingAtaxia Telangiectasia | Ataxia Telangiectasia Louis-Bar | Ataxia Telangiectasia in ChildrenUnited States
-
Johns Hopkins UniversityTerminatedAtaxia-Telangiectasia (A-T)United States
-
NHS TaysideUniversity of DundeeCompletedAtaxia-TelangiectasiaUnited Kingdom
-
St. Jude Children's Research HospitalNational Cancer Institute (NCI); Children's Hospital of PhiladelphiaCompletedAtaxia-TelangiectasiaUnited States
-
Institute of Child HealthGreat Ormond Street Hospital for Children NHS Foundation TrustCompletedAtaxia Telangiectasia (AT)United Kingdom
-
University of PlymouthRecruitingAtaxia Telangiectasia | Ataxia Telangiectasia in ChildrenUnited Kingdom
-
The University of QueenslandNational Health and Medical Research Council, AustraliaCompletedAtaxia TelangiectasiaAustralia
-
ErydelBiotrialNot yet recruitingAtaxia TelangiectasiaBelgium, United States, Denmark, Germany, Italy, Norway, Poland, Spain, United Kingdom
-
ErydelRecruitingAtaxia TelangiectasiaUnited States, Australia, Belgium, Germany, India, Italy, Poland, Spain, Tunisia
-
Acasti Pharma Inc.Active, not recruitingAtaxia TelangiectasiaCanada
Clinical Trials on Prevenar® (7-valent pneumococcal conjugate vaccine)
-
Papua New Guinea Institute of Medical ResearchThe University of Western AustraliaCompletedPneumonia | Meningitis | Otitis MediaPapua New Guinea
-
German-Jordanian UniversityWyeth is now a wholly owned subsidiary of PfizerUnknown
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedVaccines, Pneumococcal Conjugate VaccinePhilippines
-
PfizerCompletedNeisseria Meningitidis (Bacterial Meningitis) | Invasive Pneumococcal Disease (IPD)Germany
-
The Hospital for Sick ChildrenCompletedImmunosuppression | Organ TransplantCanada
-
Centers for Disease Control and Prevention, ChinaBeijing Center for Disease Control and Prevention; Beijing Municipal Health...CompletedNasopharyngeal Diseases | Streptococcal Pneumonia | Vaccination Adverse EventChina
-
National Taiwan University HospitalNational Science Council, TaiwanUnknown
-
PfizerCompletedStreptococcus Pneumoniae | Pneumococcal VaccineJapan
-
French National Agency for Research on AIDS and...Wyeth is now a wholly owned subsidiary of PfizerCompleted
-
Wyeth is now a wholly owned subsidiary of PfizerCompletedPneumococcal VaccineKorea, Republic of